lymphoma
Lymph a cikin jikin mutum yana da wuyar gaske. Lymphoma ita ce mafi sauri da mutuwa mafi girma a cikin mummunan ciwace-ciwacen daji, saboda tsarin lymphatic na jikin mutum yana da tasiri mai girma a jikin duka. Da zarar kwayoyin ciwon daji sun bayyana, za su yada tare da jini , Za a yada shi a ko'ina cikin jiki, wanda ya sa magani ya fi wuya. Magungunan da aka yi niyya na Lymphoma ba su da cikakkiyar illa. Dole ne majinyatan da ke amfani da su a hankali su lura da canje-canjen su bi da bi kuma su yi magana da likita cikin lokaci don samun damar ragewa.
Shin magungunan da aka yi niyya don lymphoma suna da tasiri?
Lymphoma na farko shine ainihin lymphoma. Lokacin amfani da magungunan da aka yi niyya, dole ne ka fara yin gwajin kwayoyin halitta akan majiyyaci. Lokacin da ka sami daidaitattun magungunan da aka yi niyya, magungunan da aka yi niyya suna da tasirin kisa kai tsaye akan ƙwayoyin cutar kansa. Amfanin shine cewa lalacewar ƙwayoyin al'ada ba ta da yawa. Ko da yake akwai sakamako masu illa da juriya na miyagun ƙwayoyi, ya dogara ne akan aikin jiki na mai haƙuri, lafiyar jiki mai kyau, babban rigakafi, da mafi kyawun maganin warkewa. Saboda haka, marasa lafiya da lymphoma dole ne su nemo hanyoyin da za su inganta aikin rigakafin su da haɓaka juriya ga ciwace-ciwacen ƙwayoyi yayin amfani da kwayoyi masu niyya.
Magungunan miyagun ƙwayoyi da aka yi niyya yana shafar tsarin nazarin halittu na sel, yin aiki ta hanyoyi daban-daban, hana ƙwayoyin cutar kansa girma ko rarrabuwa, haifar da ƙwayoyin kansa su mutu ko yin amfani da nasu tsarin rigakafi don taimakawa jiki ya kashe ƙwayoyin kansa. Idan aka kwatanta da chemotherapy, magungunan da aka yi niyya na iya yin aiki daidai akan ƙwayoyin lymphoma kuma su rage tasirin jiyya a kan ƙwayoyin lafiya, don haka rage tasirin jiyya yayin da suke da tasiri.
Menene magungunan da aka yi niyya don lymphoma?
Rituximab shine maganin rigakafi na farko da aka yi niyya wanda aka yi amfani da shi don magance lymphoma. Akwai wasu magunguna da yawa da aka yi niyya don kula da marasa lafiya tare da lymphoma, wasu an yarda da su don tallatawa, kuma yawancin magunguna har yanzu suna cikin gwaji na asibiti.
1. Ciwan cutar sankarar bargo ta kwana kwana (CLL) / karamin cutar sankarar bargo (SLL)
• Ibrutinib (Ibutinib, Imbruvica Eke)
• Idelalisib (Edelalis, Zydelig)
• Obinutuzumab (Atoruzumab, Gazyva)
Rituximab (rituximab, Rituxan merova)
2. Fata (fata) T cell lymphoma
Brentuximab Vedotin (Bentuximab, Adcetris)
3. Yada babban kwayar B-cell lymphoma
Rituximab (rituximab, Rituxan merova)
4. Kwayar folmpular lymphoma
• Idelalisib (Edelalis, Zydelig)
• Obinutuzumab (Atoruzumab, Gazyva)
Rituximab (rituximab, Rituxan merova)
• Ibritumomab Tiuxetan (Timobizumab, Zevalin)
5. Classic Hodgkin lymphoma
Brentuximab Vedotin (Bentuximab, Adcetris)
• Nivolumab (Navuliu monoclonal antibody, Opdivo)
• Pembrolizumab (Pambrolizumab, Keytruda)
6. Tsarin kwayar cutar B-cell lymphoma
Rituximab (rituximab, Rituxan merova)
7. Mantle cell lymphoma
• Bortezomib (bortezomib, Velcade Velcade) Wasanni
• Ibrutinib (Ibutinib, Imbruvica Eke)
• Yankin Lenalidomide (Lenalidomide, Revlimid)
• Temsirolimus (na sirolimus, Torisel)
8. systemic anaplastic babban cell lymphoma
Brentuximab Vedotin (Bentuximab, Adcetris)
Babu wani adadi na yau da kullun don farashin ƙwayoyin maganin ƙwayoyin lymphoma
Magungunan Lymphoma da aka yi niyya galibi sune rituximab (allurar rituximab), hanyar magani kusan 10,000 ko 20,000. Specificayyadadden ya dogara da yanayin mai haƙuri. Idan babu juriya da ƙwayoyi, zaku iya ci gaba da ɗaukarsa. Idan akwai sakamako masu illa ko ƙwarin magani, kuna buƙatar dakatar ko amfani da wasu hanyoyin magani. Saboda haka, ba a daidaita farashin ba. Za a sami canje-canje.
Jini mai tsafta a cikin jiki ana gudanar dashi ne ta hanyar tsarin hematopoietic, kuma tsarin kwayar halitta shine mai sarrafawa. Akwai samfuran lantarki da yawa a yanzu, kuma radiation ko'ina yana ko'ina, kuma akwai ƙwayoyin cuta da ke bayyana a kowane lokaci. Waɗannan sune centarfafa ƙwayoyin cutar lymphoma, dole ne ku mai da hankali sosai don nisantar lymphomas a rayuwa, kuma zaɓin ƙwayoyin da aka yi niyya don ƙwayoyin cuta ba su da yawa.
